Idifarma Desarrollo Farmacéutico

What Idifarma Desarrollo Farmacéutico does

Idifarma Desarrollo Farmacéutico, founded in 2001 in Pamplona, Spain, is the legacy entity behind what is now marketed as Ardena, a privately held integrated Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO). The firm operates five facilities across Belgium (Ghent, headquarters), the United States (Somerset, New Jersey), the Netherlands (Oss at Pivot Park and Assen), and Spain (Pamplona), employing more than 700 people and having processed over 600 molecules. Its service platform is organized around four pillars: Drug Product (complex formulation, bioavailability enhancement via hot melt extrusion and spray-drying, high-potency and controlled substances, oral solid dosage forms, sterile injectables with aseptic fill-finish and lyophilization, clinical supply, and CMC regulatory services), Nanomedicine (lipid-based, polymeric and metal nanoparticles, liposomes, nanosuspensions, ADCs/XDCs), Drug Substance (PROTACs, molecular glues, conjugates, solid-state research, HPAPI), and Bioanalysis (small and large molecule biomarkers, immunogenicity, flow cytometry, qPCR, clinical trial services).

The company targets pharmaceutical and biotech sponsors facing complex drug development challenges — poorly soluble compounds, highly potent APIs, controlled substances, and advanced modalities such as lipid nanoparticles and antibody-drug conjugates — using a horizontal segmentation approach rather than focusing on a single therapeutic area. Technical differentiation rests on capabilities that are capital- and expertise-intensive to replicate, including a Somerset-based Center of Excellence in Hot Melt Extrusion, a Pamplona spray-drying operation, and a 2,200 m² GMP Annex 1 nanomedicine facility at Pivot Park built for lipid nanoparticle and precision medicine work.

Revenue is generated through professional services contracts for development, manufacturing, and bioanalytical projects spanning pre-clinical through clinical and small-scale commercial phases. Pricing is quote-based and not publicly disclosed. Go-to-market is direct enterprise field sales, with the firm emphasizing expert-to-expert consultation and content marketing (case studies, white papers, expert insights) to drive top-of-funnel engagement. The company serves over 100 international pharmaceutical and biotech clients. Ownership is private with no public listing, and a 2016 funding round included Clave Capital, Clave Mayor, SODENA, and Suanfarma Biotech as investors (amount undisclosed).

Name

Idifarma Desarrollo Farmacéutico

Legal name

Ardena

Website

https://idifarma.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

101–250 employees

Short description

Idifarma Desarrollo Farmacéutico (operating as Ardena) is a privately held integrated CDMO and bioanalytical CRO with 700+ employees across five facilities in Europe and the United States, serving over 100 pharmaceutical and biotech clients with complex formulation, nanomedicine, and bioanalysis services.

Ownership category

akta.pro rank

Headquarters

HQ city

Pamplona

HQ country

Spain

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. CDMO Services: Contract development and manufacturing services for drug product, drug substance, and nanomedicines. Revenue generated through service contracts for pharmaceutical development projects from pre-clinical through clinical and commercial phases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Idifarma Desarrollo Farmacéutico is a contract development and manufacturing organization (CDMO) providing pharmaceutical development and manufacturing services to over 100 international pharmaceutical and biotech companies. The company specializes in complex drug formulation, bioavailability enhancement, nanomedicine production, high potency compound handling, sterile injectable manufacturing, and oral solid dosage form development, with operations spanning facilities in Europe and the United States.

Product overview

Ardena is an integrated CDMO (Contract Development and Manufacturing Organization) and bioanalytical CRO that provides comprehensive pharmaceutical development services. The company operates a multi-service platform organized into four main service areas: Drug Product (covering complex formulation, bioavailability enhancement, high potency substances, oral solid dosage forms, sterile injectables, clinical trial supply, and CMC regulatory), Nanomedicine (including lipid-based nanoparticles, polymeric nanoparticles, metal nanoparticles, ADC/XDC, and CMC regulatory), Bioanalysis (spanning small/large molecule biomarkers, immunogenicity, flow cytometry, qPCR, and clinical trial services), and Drug Substance (covering PROTACs, glues, conjugates, solid state research, and HPAPI). The platform also includes dedicated facilities for clinical supply and regulatory services. Key capabilities include process chemistry and scale-up, GMP manufacturing, and aseptic fill-finish operations.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Pivot ParksupportingStrategic or Co-development PartnerArdena has expanded capabilities with a new nanomedicine facility at Pivot Park in Oss, Netherlands. Built to GMP Annex 1 standards, the 2,200 m² facility features advanced cleanrooms, integrated development and analytical labs, and dedicated warehousing.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Lonza: One of the world's largest CDMOs across small molecules, biologics, and cell/gene therapy. Competes with Ardena across drug product and drug substance services, though at much greater scale and with a broader modality portfolio.
• WuXi STA: China-based global CDMO offering API manufacturing, drug product, and integrated services. Competes with Ardena on complex small molecules and HPAPI capabilities, though currently subject to US BIOSECURE Act-related headwinds that may benefit European peers.
• Thermo Fisher Scientific (Patheon CDMO): Through its Patheon business, Thermo Fisher offers one of the broadest CDMO service portfolios globally including drug substance, drug product, and clinical supply. Competes with Ardena across nearly all service lines but at vastly greater scale and integration with life sciences tools.

Direct peers

• Catalent: Global CDMO offering drug product development, biologics, oral and injectable formulations, and softgel technologies. Directly comparable as a full-service CDMO serving similar pharma and biotech customers with overlapping capabilities in complex formulations and sterile fill-finish.
• Recipharm: European-headquartered CDMO offering solid dose, sterile, and semi-solids manufacturing plus bioanalysis-adjacent services. Direct peer given overlapping European footprint, oral solid dose expertise, and similar customer mix in pharma and biotech.
• Hovione: Portugal-headquartered CDMO specializing in complex APIs, particle engineering, spray-drying, and bioavailability enhancement. Highly comparable to Ardena given shared focus on poorly soluble drugs, HPAPI handling, and integrated drug substance/drug product offerings.
• PCI Pharma Services: Global CDMO providing clinical and commercial drug product manufacturing, packaging, and serialisation. Comparable on clinical supply services and aseptic fill-finish capabilities, with overlapping biotech and pharma customer base.
• Aenova Group: German CDMO focused on solid and semi-solid dosage forms, sterile liquids, and biologics. Direct competitor in European CDMO market with overlapping oral solid dose and complex formulation capabilities.
• Cambrex: US-based CDMO specializing in small molecule API development and manufacturing, including controlled substances and HPAPI. Comparable on drug substance expertise, HPAPI handling, and complex molecule focus; private-owned by Permira.
• Siegfried Holding: Swiss CDMO providing API and finished drug product manufacturing, including sterile fill-finish and HPAPI capabilities. Comparable on integrated drug substance/drug product model and European manufacturing footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights1 record

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Idifarma Desarrollo Farmacéutico